CryoLife Seeks Canadian Marketing Approval for BioGlue Surgical Adhesive; BioGlue Now in Use in 33 Countries

July 28, 1999

ATLANTA--(BW HealthWire)--July 28, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has submitted a Medical Device License Application to the Canadian Government's Therapeutic Products Programme (TPP) for the use of BioGlue(R) surgical adhesive in vascular and pulmonary repair. The TPP is comparable to the United States' Food & Drug Administration (FDA).

Approval of the Medical Device License Application would make BioGlue surgical adhesive commercially available to physicians in Canada. The approval process can take a minimum of 75 days. Under Canadian regulations, five hospitals have obtained approval under TPP's Special Access Program (SAP) to use BioGlue surgical adhesive. Additional hospitals will be able to apply for SAP while CryoLife's Medical Device License Application is awaiting approval.

Steven G. Anderson, President and Chief Executive Officer of CryoLife, said, "The filing of this application is another step in making BioGlue available to physicians around the world. To date, BioGlue is in use in 33 countries."

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive, CE marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The Company also manufactures CryoLife-O'Brien(R) and CryoLife-Ross(TM) stentless porcine heart valves which are distributed within the European Community.

Statements made in this press release which look forward in time involve risks and uncertainties and are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such risks and uncertainties include the possibility that the Therapeutic Products Programme will not approve the Medical Device Application on a timely basis or at all, or if approved, that Canadian surgeons may choose not to utilize BioGlue surgical adhesive, the possibility that BioGlue surgical adhesive could have currently unforeseen side effects which could render it undesirable for use in vascular and pulmonary applications, changes in economic cycles, competition from other companies, changes in laws and governmental regulations applicable to the Company, and other risk factors detailed in the Company's Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended December 31, 1998.

Editor's Note: CryoLife Customer Service may be accessed by telephone: 1-800-438-8285 (U.S. and Canada) 1-770-419-3355 (International) 1-770-590-3753 (International fax) E-mail: customerservice@cryolife.com

For additional information about the Company,

visit CryoLife's web site:

http://www.cryolife.com

CONTACT: CryoLife Inc., Atlanta
Roy Vogeltanz, 800/438-8285